The lnterleukin-11 receptor a as a candidate ligand-directed target in osteosarcoma: Consistent data from cell lines, orthotopic models, and human tumor samples

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1995-1999

  Lewis, Valerae O ^a,d   Ozawa, Michael G ^b   Deavers, Michael T ^c   Wang, Guiying ^a   Shintani, Tomo ^d   Arap, Wadih ^b,d   Pasqualini, Renata ^b,d  

^a Section of Orthopedic Oncology   (United States)

^b David H Koch Center   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMING RECEPTOR; INTERLEUKIN 11 RECEPTOR ALPHA; IL11RA PROTEIN, HUMAN; LIGAND;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CANCER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG; LUNG METASTASIS; METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIBIA; ANIMAL; BONE TUMOR; CHEMISTRY; LUNG TUMOR; MALE; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; LIGANDS; LUNG NEOPLASMS; MALE; MICE; OSTEOSARCOMA;

EID: 62449095801     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4845     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130
2. Benjamin R, Chawla S, Murray J, et al. Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indica-tions. In: Jones S, Salmon S, editors. Adjuvant therapy of cancer IV. Philadelphia: Grune and Strattonl 1.984. p. 601-610
3. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prog-nostic factors derived, from a 10-year experience. J Clin Oncol 1990;8:1988-1997.
4. McGary EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8:3584-3591
5. Raile K1 Höflich A1 Kessler U, et al. Human osteosarco-ma (U-2 OS) cells express both insulln-llke growth factor-I (IGF-I) receptors and insulin-like growth factor-II/ mannose-6-phosphate (IGF-II/M6P) receptors and syn-thesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 1994;159:531-541
6. Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-I serum levels. J Pediatr Hematol Oncol 2002;24:440-446
7. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phophonate: low toxicity of skeletal Irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-196
8. Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 1987:47:5377-5381
9. Modak S, Kramer K, Gultekin SH, Guo Hl', Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen, expressed by a wide spectrum of human solid tumors. Cancer Res 2001;61:4048-4054
10. Aird WC. Phenotypic heterogeneity of the endothe-lium: I. structure, function, and mechanisms. Clrc Res 2007;100:158-173
11. Aird WC. Phenotypic heterogeneity of the endothe-lium: II. Representative vascular beds. Clrc Res 2007:100: 174-190
12. Ozawa MG, Zurita AJ, Dlas-Neto E, et al. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodellvery sys-tems. Trends Cardiovasc Med 2008;18:126-132
13. Arap W, Kolonin MG, Trepei M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-127
14. Pentz RD, Flamm AL, Pasqualini R, Logothetls CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 2003;33:20-26
15. Pentz RD, Cohen CB, Wicclair M, et al. Ethics guidelines for research with the recently dead. Nat Med 2005;11:1145-1149
16. Cardó-Vila M, Zurita AJ, Giordano RJ, et al. A ligand peptide motif selected from, a cancer patient is a receptor-interacting site within human interleukin-11. PLoS ONE 2008;3:e3452.
17. Zurita AJ, Troncoso P, Cardó-Vila M, et al. Combina-torial screenings in patients: the interleukin-11 receptor a as a candidate target In. the progression of human prostate cancer. Cancer Res 2004;64:435-439
18. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003:3:537-549
19. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL, Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotoplcally Into bone of athymlc mice. Cancer Res 1993:53:4890-4895
20. Hanavadi S, Martin TA, Watkins G, Maneei RE, Jiang WG. Expression of interleukin 11 and its receptor and their prognostic value In human breast cancer. Ann Surg Oncol 2006;13:802-808
21. Mohamedali KA, Kedar D, Sweeney P, et al. The vascular-targeting fusion toxin. VEGF12I/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 2008;7:912-920
22. Arap W, Pasqualini R, Ruoslahtl E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-380
23. Kolonin MG, Sana PK, Chan L, Pasqualini R, Arap W. Reversal, of obesity by targeted ablation of adipose tissue. Nat Med 2004;10:625-632
24. Arap MA, Lahdenranta J, Mintz PJ, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004;6:275-284
25. Luu HH, Rang Q, ParkJK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmo-nary metastasis. Clin Exp Metastasis 2005;22:319-329
26. Rajotte D, Arap W, Hagedorn E, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998:102:430-437
27. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-546